Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2012Leukemia & lymphoma/Leukemia and lymphomaOpen Access

MGA, a suppressor ofMYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLorenzo De PaoliUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro”MCMichaela CerriUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro”SMSara MontiUniversity of Milan

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Paoli et al. (2012) studied this question.

synapsesocial.com/papers/6a7feca91024bacc96927752https://doi.org/10.3109/10428194.2012.723706
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness2009 · 311 citations
  2. 2Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome2009 · 229 citations
  3. 3MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis2008 · 80 citations
  4. 4Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia2012 · 287 citations
  5. 5Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness2011 · 372 citations